How seriously do patients consider stem cell clinical trials? This is the first in a new series of posts I’m doing in lessons I’ve learned from the ever-increasing number of patients who contact me directly or are readers of this blog who make great comments. Today’s post is focused on the lack of availability of […]
Lessons from patients: stem cell clinical trials unlikely option for most patients Read More »
What is the Model stem cell patient advocate? I deal with many patient advocates and that is one of my favorite parts of my job. They are wonderful! However some go above and beyond the call of duty and are model advocates in my opinion. Others do some great things, but also some negative things
Model stem cell patient advocate: what are the key elements of success? Read More »
I’m doing this series called “The Elephant in the Lab” where I discuss controversial or taboo laboratory topics that people are usually too afraid to publicly discuss. I started with iPS cells (for a description and definition of iPS cells go here) and now have updated this post for 2013 because the field is changing rapidly. iPS
Taboo topics about iPS cells: updated for 2013 Read More »
The Knoepfler Lab 2012 Stem Cell Person of the Year is Roman Reed. Congratulations, Roman Reed! Roman made a tremendous difference in 2012 in many ways. One of the most notable was catalyzing the TJ Atchison Spinal Cord Injury Research Act in Alabama, which provides $400,000/year in funding for research. Of course, TJ and many
Stem Cell Person of the Year 2012: Roman Reed Read More »
I’ve already talked with science writer Ed Yong about the new Nature iPS cell paper Araki, et al. (you can read Ed’s well-written piece here and you can another one on it by another one of my favorite writers, Monya Baker here), which suggests that iPS cells don’t trigger much in the way of an immune
Some thoughts on the Araki Nature iPS cell paper: an advance, but a few key caveats Read More »
In the coming weeks and months, I am going to run a series of posts (some interviews, some guest posts) on human cloning, the reproductive type. This is the kind of cloning where you take a person (living or dead) such as, let’s say Lady GaGa or Jesus, and you try to make a duplicate
Series on scientific & bioethics leaders discussing human cloning Read More »
Today the Supreme Court agreed to review three cases, none of which were Sherley v Sebelius. What a great day! For those curious, Certiorari Granted (subheading on Supreme Court announcement) means the Court has granted review of these cases. This is wonderful news for patients, the stem cell field, and probably biotech Advanced Cell Technology
Great news as Sherley v Sebelius officially over: Supreme Court Takes a pass Read More »
The buzz topic in the stem cell field right now is whether the U.S. Supreme Court (SCOTUS) will take up the Sherley v Sebelius (S v S) case over the legality of federal funding of embryonic stem cell research in the U.S. The SCOTUS decision as to whether to hear the S v S should
Sherley v Sebelius: Will SCOTUS hear the case? What happens if it does? Read More »
Behind the scenes I get a lot of emails from employers in the stem cell/cell therapy/regenerative medicine fields looking for good prospective employees I might know. At the same time, I get a lot of emails from job seekers asking me to let them know if there are any openings I might know about. I’ve
Stem cell jobs page: free postings for job openings & seekers Read More »
Businessweek just published a very long, interesting article on Celltex by Susan Berfield yesterday. I was happy to talk with Susan at length about the key issues and be quoted in the article. See image at left of two key Celltex leaders, David Eller, CEO of Celltex, and Stan Jones above (Photograph by Thomas Prior
Nuggets and pyrite in Businessweek article on Celltex Read More »